$0.4
9.88%
Downside
Day's Volatility :9.88%
Upside
0.0%
53.75%
Downside
52 Weeks Volatility :94.15%
Upside
87.34%
Period | Entero Therapeutics Inc | Index (Russel 2000) |
---|---|---|
3 Months | -83.83% | 0.0% |
6 Months | -86.74% | 0.0% |
1 Year | -86.74% | 0.0% |
3 Years | -86.74% | -22.3% |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | 0.0% |
Return On Equity TTM | 0.0% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | 0.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
Sell
Neutral
Buy
Entero Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Entero Therapeutics Inc | -36.6% | -86.74% | -86.74% | -86.74% | -86.74% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Entero Therapeutics Inc | NA | NA | NA | 0.0 | 0.0 | 0.0 | NA | NA |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Entero Therapeutics Inc | NA | $1.4M | -86.74% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
azurrx biopharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. ms1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. the company is headquartered in new york, ny, with scientific operations based in langlade, france.
Organization | Entero Therapeutics Inc |
Employees | 9 |
CEO | Mr. James R. Sapirstein M.B.A., R.Ph. |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$0.40
-2.3%
Keyarch Acquisition Corp
$0.40
-2.3%
Connexa Sports Technologies Inc
$0.40
-2.3%
Us Value Etf
$0.40
-2.3%
First Wave Biopharma Inc
$0.40
-2.3%
Global X Msci Next Emerging
$0.40
-2.3%
Fat Projects Acquisition Corp
$0.40
-2.3%
Capital Link Global Fintech
$0.40
-2.3%
Applied Uv Inc
$0.40
-2.3%